Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4716 - Effect on quality of life (QOL) of adding cisplatin to single-agent first-line chemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC). A joint analysis of the multicentre, randomized, phase 3 MILES-3 and MILES-4 studies.

Date

09 Sep 2017

Session

Poster display session

Presenters

Maria Carmela Piccirillo

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

M.C. Piccirillo1, A. Morabito2, P. Maione3, A. Luciani4, L. Cavanna5, L. Bonanno6, E. Piazza7, S. Leo8, S. Cinieri9, F. Morgillo10, M.A. Burgio11, D. Bilancia12, F. Rosetti13, A. Montanino2, A. Manzo2, L. Arenare1, S. Signoriello14, C. Gallo14, F. Perrone1, C. Gridelli3

Author affiliations

  • 1 Clinical Trials Unit, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione Pascale, 80131 - Napoli/IT
  • 2 Thoraco-pulmonary Oncology, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione Pascale, 80131 - Napoli/IT
  • 3 Medical Oncology, Azienda Ospedaliera S. Giuseppe Moscati, 83100 - Avellino/IT
  • 4 Medical Oncology, Azienda Ospedaliera S. Paolo, 20142 - Milano/IT
  • 5 Medical Oncology, Azienda Ospedaliera Piacenza, 29121 - Piacenza/IT
  • 6 Medical And Experimental Oncology Department, Medical Oncology 2, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 7 Medical Oncology Unit, AOU Sacco Hospital, Milano/IT
  • 8 Geriatric Oncology, Ospedale Vito Fazzi, 73100 - Lecce/IT
  • 9 Medical Oncology Unit A, Perrino Hospital, 72100 - Brindisi/IT
  • 10 Dipartimento Medico-chirurgico Di Internistica Clinica E Sperimentale "f. Magrassi E A. Lanzara", Università degli Studi della Campania "Luigi Vanvitelli", 80131 - naples/IT
  • 11 Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola/IT
  • 12 Medical Oncology, AZ. OSPEDALIERA SAN CARLO, 85100 - Potenza/IT
  • 13 Oncologia Ed Ematologia Oncologica, Mirano ULSS 3, Serenissima Regione Veneto, 30035 - Mirano/IT
  • 14 Medical Statistics, Università degli Studi della Campania "Luigi Vanvitelli", 80131 - naples/IT
More

Resources

Abstract 4716

Background

The effect on QOL of adding platinum to first line treatment of elderly patients (pts) with advanced NSCLC is unknown. In this setting, MILES-3 and MILES-4 trials prospectively showed that adding cisplatin (Cis) to single-agent gemcitabine (Gem) or pemetrexed (Pem) does not significantly prolong overall survival.

Methods

Advanced NSCLC pts, >70 years old, ECOG performance status 0-1, were eligible. In MILES-3, pts with any tumor histology were randomly assigned to CisGem or Gem. In MILES-4, pts with non-squamous histology were randomly assigned to CisGem, Gem, CisPem or Pem. The trials were joined together because of slow accrual. Overall survival was the primary endpoint. QOL (EORTC QLQ C30 and LC13) was a secondary endpoint. Five questionnaires were planned in MILES-3 and 7 in MILES-4; QOL was measured in both the trials at 3 time points (baseline, end cycle 1, end cycle 2) used for joint analysis. Intention-to-treat strategy was applied; analyses were adjusted for baseline QOL, stage, PS, gender, age, size of centre, trial, histotype and companion drug.

Results

Overall, 458/531 pts (86.3%) answered baseline questionnaire. Rate of missing questionnaires at end cycle 1 and 2 was slightly higher among pts receiving Cis. Mean change in fatigue after cycle 1 (P = 0.01) and in sore mouth after cycle 2 (P = 0.02) were worse with Cis. Using a 10% change from baseline as clinically relevant threshold to categorize response, alopecia was significantly worse with Cis (P = 0.05). In time to deterioration analysis with progression/death as competitive risk, sore mouth and alopecia deteriorated more with Cis (HR 1.72 95%CI 1.02-2.89 P = 0.04 and HR 1.84 95%CI 1.09-3.10, P = 0.02, respectively). Response analysis in MILES-3 confirmed findings of the joint analysis while time to deterioration analysis in MILES-4 did not find any significant difference. Cis did not significantly improve any QOL item, in any type of analysis.

Conclusions

The addition of Cisplatin did not improve QOL of elderly patients with advanced NSCLC. Partially supported by AIFA (grant FARM8KAJZK) and Eli Lilly.

Clinical trial identification

MILES 3 EudraCT number: 2009 − 013540−36 MILES 4 EudraCT number: 2012-000164-25

Legal entity responsible for the study

Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale

Funding

Eli Lilly

Disclosure

M.C. Piccirillo: Received honoraria by Bayer for consulting and travel payment by Roche and Bayer for congresses. A. Morabito: Consulting or Advisory Role for Bristol-Myers Squibb and that received Honoraria by Roche, Boehringer Ingelheim, AstraZeneca, Lilly, Bayer, Italfarmaco and Pfizer. P. Maione: Honoraria by Lilly, Boehringer Ingelheim, AsaraZeneca and Roche, and that had Consulting or Advisory Role for Lilly, Boehringer Ingelheim, AsaraZeneca, Roche. F. Perrone: Received Travel, Accommodations, Expenses by Roche, Lilly, Bayer, Daiichi Sankyo, and received Honoraria by Amgen, Novartis, Lilly, Roche, Bayer, Daiichi Sankyo, and that his Institution had Research Funding from Roche, Bayer. C. Gridelli: Consulting Role for MSD, BMS, Celgene, Novartis, Roche, had Speakers\' Bureau from BMS, MSD, Celgene, Novartis, Roche, had Research Funding from Lilly, received Travel Expenses by MSD, BMS, Celgene, Novartis All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.